RxDoctor Payments Data

Teresa Miller

Family · Delphos, OHNPI 1154608198

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $24,200 of the $26,661 with a category attached, or 90.8%. AbbVie accounts for 97.7% of it on its own, with 20 other manufacturers making up the rest. Reporting peaked in 2021 at $19,941 and has fallen 99.3% since, to $135 in 2025. Among family clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$26,661in general payments, 2019–2025

Across 90 payments — averaging $296.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$26K
  • E.r. Squibb & Sons, L.L.C.$135
  • Takeda Pharmaceuticals U.S.A., Inc.$84
  • Johnson & Johnson$67
  • Sanofi$48
  • Lilly USA, LLC$30
  • plus $246 from 15 others

What the payments were for

  • Speaking & faculty fees$24,20091%
  • Travel & lodging$9474%
  • Food & beverage$1,5146%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$26,661 in reported general payments places this provider in the 95th percentile of 6,812 family providers in Ohio.

See all family providers in Ohio

Medicare billing

Part B allowed, 2024
$42,535
Medicare patients
217
Services billed
650

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PaxlovidNirmatrelvir/Ritonavir17$2,781
Gabapentin36$729
Levothyroxine Sodium61$602
Albuterol Sulfate HfaAlbuterol Sulfate18$597
Pantoprazole Sodium35$591
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav68$577
Metoprolol Succinate33$518
Losartan Potassium36$481
Doxycycline Hyclate38$468
Duloxetine Hcl22$401
Atorvastatin Calcium47$353
Prednisone122$268
Citalopram HbrCitalopram Hydrobromide31$254
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen12$251
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst18$236

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerPaxlovid$11$2,78117 claims
Lilly USA, LLCOlanzapine$30$10619 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,812 family providers in Ohio.

Other family in Delphos

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →